Trial Profile

A Phase I clinical trial of an undisclosed antibody candidate

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 31 Aug 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Antibody therapeutic-Merck (Primary)
Indications Cancer
Focus Adverse reactions

Most Recent Events

31 Aug 2018 New trial record
15 Aug 2018 According to an Agenus media release, Agenus received a $4 million milestone payment and is entitled to receive up to an additional $95 million in success milestones from Merck.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com